Overview

HIV Diagnosis and Treatment Market Introduction:

FutureWise Market Research has instantiated a report that provides an intricate analysis of HIV Diagnosis and Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the HIV Diagnosis and Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the HIV Diagnosis and Treatment Market:
• Viiv Healthcare Group of Companies, Inc.
• Boehringer Ingelheim Gmbh
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche Ltd
• Gilead
• Glaxosmithkline Plc.
• Hologic Inc.
• Viiv Healthcare Group of Companies, Inc.
• Janssen Diagnostics
• Johnson & Johnson Services
• Merck & Co. Inc.
• Mylan Inc.
• Qiagen
• Roche Diagnostics
• Siemens Healthcare
• Sysmex Corporation
• Zyomyx Inc.
• Partec
• Pointcare Technologies Inc.
(Note: The list of the major players will be updated with the latest market scenario and trends)

HIV Diagnosis and Treatment Market Segmentation:
By Test Type
• Antibody Tests
    • Hiv-1 Screening Tests
    • Hiv-1 Antibody Confirmatory Tests
    • Hiv-2 & Group O Diagnostic Tests
• Viral Identification Assays
• Cd4 Testing
• Viral Load Testing
• Early Infant Diagnostics
By Diagnostic Product
• Assays, Kits & Reagents
• Instruments
• Software & Service
• Others (Poc and Single Blood Drop Analyser)
By Treatment
• Protease Inhibitors (Pis)
• Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)
• Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (Nrtis)
• Entry or Fusion Inhibitors
• Integrase Inhibitors
• Others
By End User
• Diagnostic Laboratories
• Hospitals
• Blood Banks
• Home Care Settings
• Other End Users
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the HIV Diagnosis and Treatment Market By Test Type, By Diagnostic Product, By Treatment, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Product Type launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global HIV Diagnosis and Treatment Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of HIV Diagnosis and Treatment Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global HIV Diagnosis and Treatment Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global HIV Diagnosis and Treatment Market, By Test Type Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1. Antibody Tests
       7.1.1. Hiv-1 Screening Tests
       7.1.2. Hiv-1 Antibody Confirmatory Tests
       7.1.3. Hiv-2 & Group O Diagnostic Tests
  7.2. Viral Identification Assays
  7.3. Cd4 Testing
  7.4. Viral Load Testing
  7.5. Early Infant Diagnostics

8. Global HIV Diagnosis and Treatment Market, By Diagnostic Product Historical Analysis and Forecast 2020-2027 (USD Million)
  8.1. Assays, Kits & Reagents
  8.2. Instruments
  8.3. Software & Service
  8.4. Others (Poc and Single Blood Drop Analyser)

9. Global HIV Diagnosis and Treatment Market, By Treatment Historical Analysis and Forecast 2020-2027 (USD Million)
  9.1. Protease Inhibitors (Pis)
  9.2. Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)
  9.3. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (Nrtis)
  9.4. Entry or Fusion Inhibitors
  9.5. Integrase Inhibitors
  9.6. Others

10. Global HIV Diagnosis and Treatment Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
   10.1. Diagnostic Laboratories
   10.2. Hospitals
   10.3. Blood Banks
   10.4. Home Care Settings
   10.5. Other End Users

11. North America HIV Diagnosis and Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
  11.1. Introduction
  11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
       11.2.1. U.S.A
       11.2.2. Canada
       11.2.3. Mexico
  11.3. Market Size (USD Million) Forecast for North America 2020-2027

12. Latin America HIV Diagnosis and Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         12.2.1. Brazil
         12.2.2. Venezuela
         12.2.3. Argentina
         12.2.4. Rest of Latin America
   12.3. Market Size (USD Million) Forecast for Latin America 2020-2027

13. Europe HIV Diagnosis and Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         13.2.1. Germany
         13.2.2. U.K        
         13.2.3. France
         13.2.4. Italy
         13.2.5. Spain
         13.2.6. Russia
         13.2.7. Poland
         13.2.8. Rest of Europe
   13.3. Market Size (USD Million) Forecast for Europe 2020-2027

14. Asia Pacific HIV Diagnosis and Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   14.1. Introduction
   14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         14.2.1. Japan
         14.2.2. China
         14.2.3. India
         14.2.4. Australia and New Zealand
         14.2.5. ASEAN
         14.2.6. Rest of Asia Pacific
   14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   15.1. Introduction
   15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         15.2.1. Saudi Arabia
         15.2.2. UAE
         15.2.3. South Africa
         15.2.4. Egypt
   15.3. Market Size (USD Million) Forecast for MEA 2020-2027

16. Market Share Analysis and Competitive Landscape  
   16.1. Global Landscape - Key Players, Revenue and Presence
   16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   16.3. Global Emerging Companies
   16.4.  North America - Market Share Analysis and Key Regional Players
   16.5.  Europe - Market Share Analysis and Key Regional Players
   16.6.  Asia Pacific - Market Share Analysis and Key Regional Players
   16.7.  Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Types Offered and Financial Layouts)
   17.1. Viiv Healthcare Group of Companies, Inc.
         17.1.1. Company Overview
         17.1.2. Product Type Portfolio
         17.1.3. SWOT Analysis
         17.1.4. Financial Overview
         17.1.5. Strategic Overview
   17.2. Boehringer Ingelheim Gmbh
         17.2.1. Company Overview
         17.2.2. Product Type Portfolio
         17.2.3. SWOT Analysis
         17.2.4. Financial Overview
         17.2.5. Strategic Overview
   17.3. Bristol-Myers Squibb Company
         17.3.1. Company Overview
         17.3.2. Product Type Portfolio
         17.3.3. SWOT Analysis
         17.3.4. Financial Overview
         17.3.5. Strategic Overview
   17.4. PathoFinder BV
         17.4.1. Company Overview
         17.4.2. Product Type Portfolio
         17.4.3. SWOT Analysis
         17.4.4. Financial Overview
         17.4.5. Strategic Overview
   17.5. F. Hoffmann-La Roche Ltd
         17.5.1. Company Overview
         17.5.2. Product Type Portfolio
         17.5.3. SWOT Analysis
         17.5.4. Financial Overview
         17.5.5. Strategic Overview          
   17.6. Gilead
         17.6.1. Company Overview
         17.6.2. Product Type Portfolio
         17.6.3. SWOT Analysis
         17.6.4. Financial Overview
         17.6.5. Strategic Overview      
   17.7. Glaxosmithkline Plc.
         17.7.1. Company Overview
         17.7.2. Product Type Portfolio
         17.7.3. SWOT Analysis
         17.7.4. Financial Overview
         17.7.5. Strategic Overview
   17.8. Hologic Inc.
         17.8.1. Company Overview
         17.8.2. Product Type Portfolio
         17.8.3. SWOT Analysis
         17.8.4. Financial Overview
         17.8.5. Strategic Overview
   17.9. Viiv Healthcare Group of Companies, Inc.
         17.9.1. Company Overview
         17.9.2. Product Type Portfolio
         17.9.3. SWOT Analysis
         17.9.4. Financial Overview
         17.9.5. Strategic Overview
   17.10. Janssen Diagnostics
         17.10.1. Company Overview
         17.10.2. Product Type Portfolio
         17.10.3. SWOT Analysis
         17.10.4. Financial Overview
         17.10.5. Strategic Overview
   17.11. Johnson & Johnson Services
         17.11.1. Company Overview
         17.11.2. Product Type Portfolio
         17.11.3. SWOT Analysis
         17.11.4. Financial Overview
         17.11.5. Strategic Overview
   17.12. Merck & Co. Inc.
         17.12.1. Company Overview
         17.12.2. Product Type Portfolio
         17.12.3. SWOT Analysis
         17.12.4. Financial Overview
         17.12.5. Strategic Overview
   17.13. Mylan Inc.
         17.13.1. Company Overview
         17.13.2. Product Type Portfolio
         17.13.3. SWOT Analysis
         17.13.4. Financial Overview
         17.13.5. Strategic Overview
   17.14. Qiagen
         17.14.1. Company Overview
         17.14.2. Product Type Portfolio
         17.14.3. SWOT Analysis
         17.14.4. Financial Overview
         17.14.5. Strategic Overview
   17.15. Roche Diagnostics
         17.15.1. Company Overview
         17.15.2. Product Type Portfolio
         17.15.3. SWOT Analysis
         17.15.4. Financial Overview
         17.15.5. Strategic Overview
   17.16. Partec
         17.16.1. Company Overview
         17.16.2. Product Type Portfolio
         17.16.3. SWOT Analysis
         17.16.4. Financial Overview
         17.16.5. Strategic Overview
   17.17. Pointcare Technologies Inc.
         17.17.1. Company Overview
         17.17.2. Product Type Portfolio
         17.17.3. SWOT Analysis
         17.17.4. Financial Overview
         17.17.5. Strategic Overview
   17.18. Siemens Healthcare
         17.18.1. Company Overview
         17.18.2. Product Type Portfolio
         17.18.3. SWOT Analysis
         17.18.4. Financial Overview
         17.18.5. Strategic Overview
   17.19. Sysmex Corporation
         17.19.1. Company Overview
         17.19.2. Product Type Portfolio
         17.19.3. SWOT Analysis
         17.19.4. Financial Overview
         17.19.5. Strategic Overview
   17.20. Zyomyx Inc.
         17.20.1. Company Overview
         17.20.2. Product Type Portfolio
         17.20.3. SWOT Analysis
         17.20.4. Financial Overview
         17.20.5. Strategic Overview


18. Pre and Post COVID-19 Impact
   18.1. Positive influence on the healthcare industry
   18.2. The financial disruption of the manufacturing sector
   18.3. Impact of COVID-19 on emerging companies
   18.4. Significant mandates in the healthcare regulations initiated by administrations
   18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures